Dudnyk Expands Offering Via Strategic Acquisition
This latest acquisition signals yet another move by the agency to be the preeminent resource for biotech, biopharma, and medical device marketing managers commercializing and promoting their brands in the most challenging environment in decades.
“Specialty companies, because of their focus, can truly benefit from the creative work and sustained dedication provided by independent creative firms. Specialty companies also gain by having direct access to the higher level of scientific acumen, strategic intelligence, and commercialization expertise that Dudnyk offers,” says Frank X. Powers, president of Dudnyk. “It’s been our mission to serve these companies since we began in 1993. With increased regulations and a difficult economy, the need of specialty companies for our services has become even more urgent in the last few years. We acquired Stratagem as a way to bring enhanced value and additional resources, such as increased depth in multichannel digital capabilities to our combined client base. The acquisition represents a step forward in providing superior brand support to specialty pharma and medical device marketers.”
Dudnyk began as an independently owned healthcare agency—and it proudly remains so. The agency’s independence and self-determined financial path have resulted in its ability to remain true to its creative vision. Dudnyk has an established, proven track record of success serving smaller brands and orphan products with significant potential. “Our focus is communicating with specialty physicians and their patients in the biotech, biopharma, and medical device sectors. The Stratagem team brings us additional senior talent and experience with those audiences and sectors; additional imaging, dermatology, and medical device marketing expertise; plus a strong direct-to-patient (DTP) portfolio,” Powers adds.
With this move, Dudnyk adds some of the industry’s best Rx and DTP marketers to its mix. Key personnel joining the agency from Stratagem are Susan Hempstead as SVP, Account Management and Strategy, Patricia Malone as SVP, Creative Director, Copy, and Paul Harris as SVP, Creative Director, Art. The entire agency will operate within the structure of the powerful Dudnyk brand.
"We are thrilled to join Dudnyk, and I can already see the synergies between our teams resulting in incredible ideas and work. Dudnyk is one of the most exciting companies in the healthcare marketing community right now,” commented Ms. Hempstead. “We have deep marketing expertise and that will only strengthen Dudnyk’s incredible value to clients, and Dudnyk will bring creative, digital, and scientific energy to our clients, ZONARE Medical Systems, John Muir Health, Valeant Pharmaceuticals, and Roche Molecular Systems. We couldn’t be more thrilled to be joining forces to help Dudnyk on its mission. Everybody wins.”
More information about the leadership team, select clients, and Dudnyk’s mission to bring a deeper level of science and creativity to biotech marketing can be found at dudnyk.com.
About Dudnyk
Dudnyk is a full-service healthcare advertising agency that supports biotech, biopharma, and medical device companies. Respected in the advertising industry for Inciteful Healthcare Marketing™, Dudnyk leverages strategic, scientific, and highly creative capabilities to develop branded and unbranded multichannel communications. Dudnyk is the PM360 Advertising Agency of the Year, the winner of Med Ad News’ Best Professional Campaign, and was cited by Inc. as one of the nation’s 5000 fastest-growing private companies. Founded in 1993, Dudnyk remains fiercely independent and has offices in Philadelphia, San Diego, and San Francisco. Learn more at dudnyk.com or @DudnykHealth.